GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » E10

Iovance Biotherapeutics (Iovance Biotherapeutics) E10 : $-1.87 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Iovance Biotherapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Iovance Biotherapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.87 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 33.40% per year. During the past 5 years, the average E10 Growth Rate was 25.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Iovance Biotherapeutics was 33.40% per year. The lowest was 4.80% per year. And the median was 27.00% per year.

As of today (2024-06-06), Iovance Biotherapeutics's current stock price is $8.13. Iovance Biotherapeutics's E10 for the quarter that ended in Mar. 2024 was $-1.87. Iovance Biotherapeutics's Shiller PE Ratio of today is .


Iovance Biotherapeutics E10 Historical Data

The historical data trend for Iovance Biotherapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics E10 Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.42 -6.14 -2.60 -2.48 -1.81

Iovance Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 -1.93 -1.91 -1.81 -1.87

Competitive Comparison of Iovance Biotherapeutics's E10

For the Biotechnology subindustry, Iovance Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Shiller PE Ratio falls into.



Iovance Biotherapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Iovance Biotherapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.42/131.7762*131.7762
=-0.420

Current CPI (Mar. 2024) = 131.7762.

Iovance Biotherapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.090 100.560 -0.118
201409 -0.110 100.428 -0.144
201412 -0.180 99.070 -0.239
201503 -0.140 99.621 -0.185
201506 -0.140 100.684 -0.183
201509 -0.160 100.392 -0.210
201512 -0.200 99.792 -0.264
201603 -0.140 100.470 -0.184
201606 -0.230 101.688 -0.298
201609 -1.150 101.861 -1.488
201612 -0.250 101.863 -0.323
201703 -0.330 102.862 -0.423
201706 -0.370 103.349 -0.472
201709 -0.350 104.136 -0.443
201712 -0.360 104.011 -0.456
201803 -0.310 105.290 -0.388
201806 -0.340 106.317 -0.421
201809 -0.360 106.507 -0.445
201812 -0.270 105.998 -0.336
201903 -0.300 107.251 -0.369
201906 -0.380 108.070 -0.463
201909 -0.400 108.329 -0.487
201912 -0.500 108.420 -0.608
202003 -0.550 108.902 -0.666
202006 -0.470 108.767 -0.569
202009 -0.400 109.815 -0.480
202012 -0.470 109.897 -0.564
202103 -0.510 111.754 -0.601
202106 -0.530 114.631 -0.609
202109 -0.550 115.734 -0.626
202112 -0.630 117.630 -0.706
202203 -0.580 121.301 -0.630
202206 -0.630 125.017 -0.664
202209 -0.630 125.227 -0.663
202212 -0.640 125.222 -0.673
202303 -0.500 127.348 -0.517
202306 -0.470 128.729 -0.481
202309 -0.460 129.860 -0.467
202312 -0.450 129.419 -0.458
202403 -0.420 131.776 -0.420

Add all the adjusted EPS together and divide 10 will get our e10.


Iovance Biotherapeutics  (NAS:IOVA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Iovance Biotherapeutics E10 Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Executives
Merrill A Mcpeak director PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wayne P. Rothbaum director C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Wendy L Yarno director
Frederick G Vogt officer: General Counsel 2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes director 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon director
Ryan D Maynard director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky officer: Chief Operating Officer C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin officer: Chief Financial Officer C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg officer: VP, Finance C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf officer: Chief Medical Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris officer: Chief Financial Officer ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis director, officer: President and CEO C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085

Iovance Biotherapeutics (Iovance Biotherapeutics) Headlines